Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing
Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing
复制标题
DOI：
10.1111/trf.16268
复制
发表时间：
2021-01-25
期刊：
影响因子：
2.9
通讯作者：
Sabino, Ester Cerdeira
中科院分区：
文献类型：
--
作者：
Mendrone-Junior, Alfredo;Dinardo, Carla Luana;Sabino, Ester Cerdeira
恢复期血浆（CP）是治疗COVID-19的一种替代方法，其疗效取决于中和抗体（nAb）的高滴度，但用于定量nAb的测定方法尚未广泛使用。我们的目标是开发一种策略来预测高滴度的nAbs的基础上的抗SARS-CoV-2的免疫测定和CP donors.Study设计和方法的临床特征的结果共214 CP捐助者被招募和测试抗SARS-CoV-2抗体（IgG）的存在使用两个商业免疫测定：EUROIMMUN（ELISA）和雅培（化学发光）。使用基于致细胞病变抗体的病毒中和试验对nAb进行定量。对nAbs ≥ 1：160的供体进行了三个标准的检测：- C1：ROC曲线; - C2：仅考虑IA结果的条件决策树;- C3：包括IA结果和临床变量的条件决策树。关于鉴定具有高nAb滴度的CP供体的研究标准：（a）如果S/CO = 4.65，C1显示76.1%的准确性，（B）如果S/CO >= 4.57，则C2的准确度为76.1%，（c）如果S/CO>= 4.57或如果S/CO在2.68-4.57之间，则C3的准确度为71.6%，最后一次COVID-19-结论SARS-CoV-2 IgG免疫检测法（S/CO）可用于预测高滴度抗SARS-CoV-2 nAb。该研究提出了用于鉴定具有>= 1：160 nAb滴度的供体的不同标准，所有这些标准都具有高效力。
Background The efficacy of convalescent plasma (CP), an alternative for the treatment of COVID-19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of anti-SARS-CoV-2 immunoassays and the clinical characteristics of CP donors.Study Design and Methods A total of 214 CP donors were enrolled and tested for the presence of anti-SARS-CoV-2 antibodies (IgG) using two commercial immunoassays: EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effect-based Virus Neutralization test. Three criteria for identifying donors with nAbs >= 1:160 were tested: - C1: Curve ROC; - C2: Conditional decision tree considering only the IA results and - C3: Conditional decision tree including both the IA results and the clinical variables.Results The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers >= 1:160. Regarding the studied criteria for identifying CP donors with high nAbs titers: (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO >= 4.57 and (c) C3 had 71.6% accuracy if S/CO was >= 4.57 or if S/CO was between 2.68-4.57 and the last COVID-19-related symptoms were recent (within 19 days).Conclusion SARS-CoV-2 IgG immunoassays (S/CO) can be used to predict high anti-SARS-CoV-2 nAbs titers. This study has proposed different criteria for identifying donors with >= 1:160 nAbs titers, all with high efficacy.